TFP-PEG4-Val-Cit-PAB-MMAE acts as a precursor of antibody drug conjugate containing an amine-reactive TFP ester that is less susceptible to hydrolysis than an NHS ester. The linker-payload is comprised of a cathepsin-cleavable Val-Cit peptide, PAB spacer, and an MMAE payload. It can be attached to a monoclonal antibody (MAB) which directs it toward cancer cells.
Usually ships within 24 hours.